LIVERPOOL HEART AND CHEST HOSPITAL NHS FOUNDATION TRUST

Their core work

Liverpool Heart and Chest Hospital (LHCH) is a specialist NHS centre dedicated exclusively to cardiac, thoracic, and vascular surgery and medicine — one of the largest standalone heart and chest hospitals in Europe. Their H2020 participation reflects two distinct clinical strengths: managing complex cardiac arrhythmias through remote monitoring technologies, and performing high-risk thoracoabdominal aortic aneurysm repairs with a focus on preventing catastrophic complications such as paraplegia. As a clinical site, they contribute real-world patient populations, surgical expertise, and randomized controlled trial execution to research consortia. Their value in any consortium is direct access to patients and practicing specialists at the intersection of cardiovascular surgery, electrophysiology, and ICT-enabled care.

What they specialise in

How they've shifted over time

LHCH entered H2020 through RITMOCORE with a focus on cardiac rhythm disorders — specifically ICT-enabled remote monitoring, arrhythmia prevention, and innovative procurement models for digital health technologies. As their participation progressed, their second project (PAPA-ARTIS) shifted entirely toward complex vascular surgery: open thoracoabdominal aortic repair, spinal cord protection, and paraplegia prevention through staged surgical techniques validated in an RCT. The trajectory moves from cardiology and digital health toward high-acuity vascular and thoracic surgery, suggesting the hospital is deepening its research profile around the most technically demanding procedures it performs clinically.

LHCH is moving toward evidence-generation for complex, high-risk surgical procedures — particularly in aortic and thoracic vascular surgery — making them a relevant partner for consortia developing surgical protocols, imaging guidance, or neuroprotection technologies.

How they like to work

LHCH participates exclusively as a consortium partner, never as coordinator — a profile consistent with a clinical hospital that contributes patient access and specialist expertise rather than project administration. With 41 unique partners across 11 countries across just two projects, they operate within large, multi-site international consortia typical of RIA and PPI schemes. This suggests they are comfortable as one of several clinical sites in a distributed trial or procurement network, rather than anchoring bilateral collaborations.

LHCH has built connections with 41 unique partners across 11 countries through only two projects, indicating they join well-networked consortia rather than forming their own tight cluster. Their reach is broadly European, consistent with multi-country clinical trial networks in cardiology and vascular surgery.

What sets them apart

LHCH is one of very few standalone specialist heart and chest hospitals in Europe with documented H2020 participation, giving them a narrow but highly credible clinical niche that general university hospitals cannot replicate. Their dual capability — electrophysiology and complex aortic surgery — means they can contribute to both device-based cardiac care trials and high-risk surgical intervention studies. For consortia needing a UK NHS clinical site with real patient throughput in cardiovascular specialties, LHCH offers direct access to a concentrated volume of relevant cases.

Highlights from their portfolio

• RITMOCORE
  LHCH's highest-funded project (EUR 915,835) combining arrhythmia care with remote ICT monitoring and an innovative risk-sharing procurement model — rare at the intersection of clinical cardiology and health technology procurement.
• PAPA-ARTIS
  A long-running RCT (2017-2024) tackling one of cardiac surgery's most feared complications — post-operative paraplegia — through a staged minimally-invasive approach to thoracoabdominal aortic repair.